<DOC>
	<DOC>NCT02855775</DOC>
	<brief_summary>This Study evaluates covariables being able to potentially influence the elimination of the monoclonal antibodies (trastuzumab, bevacizumab and denosumab).</brief_summary>
	<brief_title>Monoclonal Antibodies Elimination in Breast Cancer Patient</brief_title>
	<detailed_description>Monoclonal antibodies are very widely used in cancer treatment . Certain patients benefit from these antibodies for several years and it is conceivable to wonder about the evolution of the pharmacokinetics of these antibodies.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>A diagnosed cancer patient treated by bevacizumab or trastuzumab Life expectancy of at least 3 months For the women: menopausal women for at least 24 months, sterilized surgically, or, for the women old enough to procreate, use a method of effective contraception (oral contraceptives, contraceptive injections, intrauterine devices, method of the double barrier, the contraceptive patches). This contraception will have to be pursued during 6 months after the end of the treatment by bevacizumab or by trastuzumab. For Patients treated by trastuzumab: Dyspnoea of severe rest in touch with complications due to the disease or requiring an oxygen therapy. Hypocalcemia severe untreated</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>